This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists.  There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy.  The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area.  In this volume, a variety of novel pharmaceutical treatments are examined.  This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. weiterlesen